Clinical management of severe therapy-resistant asthma

References

• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373.
   PubMed Web of Science ®Google Scholar
• Chung KF, Godard P, Adelroth E, et al. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS task force on difficult/therapy-resistant asthma. European respiratory society. Eur Respir J. 1999;13(5):1198–1208.
   Google Scholar
• Sin DD, Miravitlles M, Mannino DM, et al. What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion. Eur Respir J. 2016;48(3):664–673.
   PubMed Web of Science ®Google Scholar
• Hekking PP, Wener RR, Amelink M, et al. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896–902.
   PubMed Web of Science ®Google Scholar
• Accordini S, Bugiani M, Arossa W, et al. Poor control increases the economic cost of asthma. A multicentre population-based study. Int Arch Allergy Immunol. 2006;141(2):189–198.
   PubMed Web of Science ®Google Scholar
• O’Neill S, Sweeney J, Patterson CC, et al. The cost of treating severe refractory asthma in the UK: an economic analysis from the British thoracic society difficult asthma registry. Thorax. 2015;70(4):376–378.
   PubMed Web of Science ®Google Scholar
• Robinson DS, Campbell DA, Durham SR, et al. Systematic assessment of difficult-to-treat asthma. Eurrespir J. 2003;22(3):478–483.
   PubMed Web of Science ®Google Scholar
• Radhakrishna N, Tay TR, Hore-Lacy F, et al. Profile of difficult to treat asthma patients referred for systematic assessment. Respir Med. 2016;117:166–173.
   PubMed Web of Science ®Google Scholar
• Shaw DE, Sousa AR, Fowler SJ, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015;46(5):1308–1321.
   PubMed Web of Science ®Google Scholar
• Sweeney J, Patterson CC, Menzies-Gow A, et al. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. Thorax. 2016;71(4):339–346.
   PubMed Web of Science ®Google Scholar
• Radhakrishna N, Tay TR, Hore-Lacy F, et al. Validated questionnaires heighten detection of difficult asthma comorbidities. J Asthma. 2017; in press.
   Google Scholar
• Tay TR, Radhakrishna N, Hore-Lacy F, et al. Comorbidities in difficult asthma are independent risk factors for frequent exacerbations, poor control and diminished quality of life. Respirology. 2016;21(8):1384–1390.
   PubMed Web of Science ®Google Scholar
• Gibeon D, Heaney LG, Brightling CE, et al. Dedicated severe asthma services improve health-care use and quality of life. Chest. 2015;148(4):870–876.
   PubMed Web of Science ®Google Scholar
• Sweeney J, Brightling CE, Menzies-Gow A, et al. Clinical management and outcome of refractory asthma in the UK from the British thoracic society difficult asthma registry. Thorax. 2012;67(8):754–756.
   PubMed Web of Science ®Google Scholar
• Gamble J, Stevenson M, McClean E, et al. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med. 2009;180(9):817–822.
   PubMed Web of Science ®Google Scholar
• Murphy AC, Proeschal A, Brightling CE, et al. The relationship between clinical outcomes and medication adherence in difficult-to-control asthma. Thorax. 2012;67(8):751–753.
   PubMed Web of Science ®Google Scholar
• Williams LK, Peterson EL, Wells K, et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol. 2011;128(6):1185–91e2.
   PubMed Web of Science ®Google Scholar
• McNicholl DM, Stevenson M, McGarvey LP, et al. The utility of fractional exhaled nitric oxide suppression in the identification of nonadherence in difficult asthma. Am J Respir Crit Care Med. 2012;186(11):1102–1108.
   PubMed Web of Science ®Google Scholar
• Pilcher J, Holliday M, Ebmeier S, et al. Validation of a metered dose inhaler electronic monitoring device: implications for asthma clinical trial use. BMJ Open Respir Res. 2016;3(1):e000128.
   Google Scholar
• Pilcher J, Shirtcliffe P, Patel M, et al. Three-month validation of a turbuhaler electronic monitoring device: implications for asthma clinical trial use. BMJ Open Respir Res. 2015;2(1):e000097.
   PubMed Web of Science ®Google Scholar
• Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18(5):716–725.
   PubMed Web of Science ®Google Scholar
• Chung KF. Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies. J Intern Med. 2016;279(2):192–204.
   PubMed Web of Science ®Google Scholar
• Nair P, Dasgupta A, Brightling CE, et al. How to diagnose and phenotype asthma. Clin Chest Med. 2012;33(3):445–457.
   PubMed Web of Science ®Google Scholar
• Chung KF. Inflammatory biomarkers in severe asthma. Curr Opin Pulm Med. 2012;18(1):35–41.
   PubMed Web of Science ®Google Scholar
• Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma phenotype by the national heart, lung, and blood institute’s severe asthma research program. J Allergy Clin Immunol. 2007;119(2):405–413.
   PubMed Web of Science ®Google Scholar
• Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Amer J Resp Crit Care Med. 2008;178(3):218–224.
   PubMed Web of Science ®Google Scholar
• Lefaudeux D, De Meulder B, Loza MJ, et al. U-BIOPRED clinical adult asthma clusters linked to a subset of sputum -omics. J Allergy Clin Immunol. 2017; in press.
   Google Scholar
• Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med. 2010;181(4):315–323.
   PubMed Web of Science ®Google Scholar
• Cowan DC, Taylor DR, Peterson LE, et al. Biomarker-based asthma phenotypes of corticosteroid response. J Allergy Clin Immunol. 2015;135(4):877–83e1.
   PubMed Web of Science ®Google Scholar
• De Groot JC, Ten BA, Bel EH. Management of the patient with eosinophilic asthma: a new era begins. ERJ Open Res. 2015;1:1.
   Google Scholar
• Eosinophilic Lung CV. Diseases. Clin Chest Med. 2016;37(3):535–556.
   PubMed Web of Science ®Google Scholar
• Chung KF, Adcock IM. Clinical phenotypes of asthma should link up with disease mechanisms. Curr Opin Allergy Clin Immunol. 2015;15(1):56–62.
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Amjrespir Crit Care Med. 2009;180(5):388–395.
   PubMed Web of Science ®Google Scholar
• Pavlidis S. LM, Baribaud F, Kuo C-H, et al. Th2 subsetting of U-BIOPRED asthma subjects based on airway transciptomic profiles. Eur Respir J. 2015;46(Suppl59):OA1772. doi:10.183/13993003.congress-2015
   Google Scholar
• Kuo CS, Pavlidis S, Loza M, et al. A transcriptome-driven analysis of epithelial brushings and bronchial biopsies to define asthma phenotypes in U-BIOPRED. Am J Respir Crit Care Med. 2017;195(4):443–455.
   PubMed Web of Science ®Google Scholar
• Kuo CS, Pavlidis S, Loza M, et al. T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED. Eur Respir J. 2017;49:2.
   Web of Science ®Google Scholar
• Macedo P, Hew M, Torrego A, et al. Inflammatory biomarkers in airways of patients with severe asthma compared with non-severe asthma. Clin Exp Allergy. 2009;39(11):1668–1676.
   PubMed Web of Science ®Google Scholar
• Jatakanon A, Uasuf C, Maziak W, et al. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med. 1999;160(5 Pt 1):1532–1539.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Brightling CE, Woltmann G, et al. Non-eosinophilic corticosteroid unresponsive asthma. Lancet. 1999;353(9171):2213–2214.
   PubMed Web of Science ®Google Scholar
• Moore WC, Hastie AT, Li X, et al. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin Immunol. 2014;133(6):1557–63e5.
   PubMed Web of Science ®Google Scholar
• Fahy JV, Kim KW, Liu J, et al. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol. 1995;95(4):843–852.
   PubMed Web of Science ®Google Scholar
• Nguyen LT, Lim S, Oates T, et al. Increase in airway neutrophils after oral but not inhaled corticosteroid therapy in mild asthma. Respir Med. 2005;99(2):200–207.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Metev H, Puu M, et al. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2016;4(10):797–806.
   PubMed Web of Science ®Google Scholar
• Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. 2013;68(4):322–329.
   PubMed Web of Science ®Google Scholar
• Hew M, Chung KF. Corticosteroid insensitivity in severe asthma: significance, mechanisms and aetiology. Intern Med J. 2010;40(5):323–334.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? the gaining optimal asthma control study. Amj Respir Crit Care Med. 2004;170(8):836–844.
   PubMed Web of Science ®Google Scholar
• Gibeon D, Batuwita K, Osmond M, et al. Obesity-associated severe asthma represents a distinct clinical phenotype: analysis of the British Thoracic Society Difficult Asthma Registry Patient cohort according to BMI. Chest. 2013;143(2):406–414.
   PubMed Web of Science ®Google Scholar
• Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360(9347):1715–1721.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197.
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Disse B, Schroder-Babo W, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol. 2011;128(2):308–314.
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367(13):1198–1207.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Wenzel S, Rosen K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804–811.
   PubMed Web of Science ®Google Scholar
• Chung KF. Targeting the interleukin pathway in the treatment of asthma. Lancet. 2015;386(9998):1086–1096.
   PubMed Web of Science ®Google Scholar
• Wang FP, Liu T, Lan Z, et al. Efficacy and Safety of Anti-Interleukin-5 Therapy in Patients with Asthma: A Systematic Review and Meta-Analysis. Plos One. 2016;11(11):e0166833.
   PubMed Web of Science ®Google Scholar
• Pretolani M, Bergqvist A, Thabut G, et al. Effectiveness of bronchial thermoplasty in patients with severe refractory asthma: clinical and histopathologic correlations. J Allergy Clin Immunol. 2017;139:1176–1185.
   PubMed Web of Science ®Google Scholar
• Burn J, Sims AJ, Keltie K, et al. Procedural and short-term safety of bronchial thermoplasty in clinical practice: evidence from a national registry and Hospital Episode Statistics. J Asthma. 2017; in press.
   Google Scholar
• Heaney LG, Djukanovic R, Woodcock A, et al. Research in progress: medical research council united kingdom refractory asthma stratification programme (RASP-UK). Thorax. 2016;71(2):187–189.
   PubMed Web of Science ®Google Scholar
• Jarjour NN, Erzurum SC, Bleecker ER, et al. Severe asthma: lessons learned from the national heart, lung, and blood institute severe asthma research program. Am J Respir Crit Care Med. 2012;185(4):356–362.
   PubMed Web of Science ®Google Scholar
• Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47(2):410–419.
   PubMed Web of Science ®Google Scholar
• Zhang H, Gustafsson M, Nestor C, et al. Targeted omics and systems medicine: personalising care. Lancet Respir Med. 2014;2(10):785–787.
   PubMed Web of Science ®Google Scholar